LifeArc invests in Maxion Therapeutics Series A
Sohaib Mir, Partner at LifeArc Ventures, congratulates portfolio company, Maxion Therapeutics, on their
successful $72 million Series A funding.
Sohaib Mir, Partner at LifeArc Ventures, said:
“We are delighted to continue to back Maxion’s team as they progress their KnotBody platform into the
clinic. The calibre of international investors in the $72 million Series A is testament to the potential of
Maxion’s unique approach which we believe can be transformative in the treatment of multiple ion
channel- and GPCR-driven diseases.”
